Comparison of the ADVIA centaur® and Abbott AxSYM immunoassay systems for a routine diagnostic virology laboratory

Taylor, Paul J.; Pickard, Graham; Gammie, A. J.

doi:10.1016/j.jcv.2004.02.004

Cited by 11 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is higher than previously published data; the throughputs of the Architect, Elecsys and Vitros ECi under routine conditions were 123, 97 and 46 tests/h, respectively, 15 and 102 for the Advia Centaur. 16 Finally, the UniCel DxI 800 fulfills the requirements of the Common Technical Specifications of the European Union for the HCV and HBV serological markers tested in our laboratory evaluation. It also combines practical convenience and probably the best throughput for this type of analyser.…”

Section: Discussionmentioning

confidence: 97%

Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers

Miédougé¹,

Abravanel²,

Lalanne³

et al. 2009

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers

Miédougé¹,

Abravanel²,

Lalanne³

et al. 2009

Journal of Clinical Virology

View full text Add to dashboard Cite

“…Although quantitative virus detection is always desired, this limitation is not important in the context of using the novel sensor as a qualitative, rapid screening, high throughput assay. Using a multiple cell-electrode interface array (currently under testing by our research group), it is possible to conduct more than 1,150 individual tests/h, a capacity considerably larger than with conventional immunoassay systems (80–100 test/h) [24]. In addition, the novel cell biosensor has the advantage of increased storability, since immobilized, membrane-engineered cells can be maintained alive for up to four weeks after provision of 20 (v/v) fetal calf serum [25].…”

Section: Discussionmentioning

confidence: 99%

Development of a Novel, Ultra-rapid Biosensor for the Qualitative Detection of Hepatitis B Virus-associated Antigens and Anti-HBV, Based on “Membrane-engineered” Fibroblast Cells with Virus-Specific Antibodies and Antigens

Perdikaris,

Alexandropoulos,

Kintzios

2009

Sensors

View full text Add to dashboard Cite

A novel miniature cell biosensor detection system for the detection of Hepatis B virus (HBV)-associated antigens and anti-HBV is described. The biosensor is based on “membrane-engineered” Vero fibroblast cells immobilized in an alginate matrix. The membrane-engineering process involved the electroinsertion of anti-HBV specific antibodies (anti-HBs, anti-HBe) or antigens (HBsAg) in the membranes of the Vero cells. The attachment of a homologous antigen to the electroinserted antibody (or, respectively, of the antibody to the electroinserted antigen) triggered specific changes to the cell membrane potential that were measured by appropriate microelectrodes, according to the principle of the Bioelectric Recognition Assay (BERA). The sensor was used for screening 133 clinical blood serum samples according to a double-blind protocol. Considerably higher sensor responses were observed against HBV-positive samples, compared with responses against negative samples or samples positive for heterologous hepatitis viruses such as Hepatitis C (HCV) virus. Detection of anti-HBs antibodies was made possible by using a biosensor based on immobilized Vero cells bearing the respective antigen (HBsAg). The observed response was rapid (45 sec) and quite reproducible. Fluorescence microscopy observations showed that attachment of HBV particles to cells membrane-engineered with anti-HBs was associated with a decrease of [Ca2+]cyt. The perspectives for using the novel biosensor as a qualitative, rapid screening, high throughput assay for HBV antigens and anti-HBs in clinical samples is discussed.

show abstract

“…Widely distributed signage and flyers in admission papers informed patients about HCV screening and offered the opportunity to opt out. For anti‐HCV antibody testing, the Advia Centaur HCV Assay (Bayer HealthCare LLC, Tarrytown, NY) was used; its sensitivity is 99.9% and specificity is 97.5% . Following expert guidelines when the anti‐HCV test was positive (reactive), a reflex HCV RNA assay was performed using the COBAS AmpliPrep/COBAS TaqMan HCV Test (Roche Molecular Systems, Pleasanton, CA).…”

Section: Methodsmentioning

confidence: 99%

“…For anti-HCV antibody testing, the Advia Centaur HCV Assay (Bayer HealthCare LLC, Tarrytown, NY) was used; its sensitivity is 99.9% and specificity is 97.5%. 12,13 Following expert guidelines 14 when the anti-HCV test was positive (reactive), a reflex HCV RNA assay was performed using the COBAS AmpliPrep/COBAS TaqMan HCV Test (Roche Molecular Systems, Pleasanton, CA). For most patients, both tests were performed on the same specimen.…”

Section: Setting and Proceduresmentioning

confidence: 99%

High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers

et al. 2015

View full text Add to dashboard Cite

Low-income populations are disproportionately affected by hepatitis C virus (HCV) infection. Thus, implementing baby boomer screening (born 1945-1965) for HCV may be a high priority for safety net hospitals. We report the prevalence and predictors of HCV infection and advanced fibrosis or cirrhosis based on the Fibrosis-4 score plus imaging for a baby boomer cohort admitted to a safety net hospital over a 21-month interval with >9 months of follow-up. Anti-HCV antibody testing was performed for 4582, or 90%, of all neverscreened patients, of whom 312 (6.7%) tested positive. Adjusted odds ratios of testing anti-HCV-positive were 2.66 for men versus women (P < 0.001), 1.25 for uninsured versus insured (P 5 0.06), 0.70 for Hispanics versus non-Hispanic whites (P 5 0.005), and 0.93 per year of age (P < 0.001). Among 287 patients tested for HCV RNA (91% of all anti-HCVpositive cases), 175 (61%) were viremic (3.8% overall prevalence in cohort), which was 5% less likely per year of age (P < 0.03). Noninvasive staging of 148 (84.6%) chronic HCV patients identified advanced fibrosis or cirrhosis in 50 (33.8%), with higher adjusted odds ratios of 3.21 for Hispanics versus non-Hispanic whites/Asians (P 5 0.02) and 1.18 per year of age (P 5 0.001). Other factors associated with significantly higher adjusted odds ratios of advanced fibrosis or cirrhosis were alcohol abuse/dependence, obesity, and being uninsured. Conclusion: In this low-income, hospitalized cohort, 4% of 4582 screened baby boomers were diagnosed with chronic HCV, nearly twice the rate in the community; one-third had noninvasive testing that indicated advanced fibrosis or cirrhosis, which was significantly more likely for Hispanics, those of older age, those with obesity, those with alcohol abuse/ dependence, and those who lacked insurance. (HEPATOLOGY 2015;62:1388-1395

show abstract

Comparison of the ADVIA centaur® and Abbott AxSYM immunoassay systems for a routine diagnostic virology laboratory

Cited by 11 publications

References 5 publications

Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers

Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers

Development of a Novel, Ultra-rapid Biosensor for the Qualitative Detection of Hepatitis B Virus-associated Antigens and Anti-HBV, Based on “Membrane-engineered” Fibroblast Cells with Virus-Specific Antibodies and Antigens

High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers

Contact Info

Product

Resources

About